Literature DB >> 16505361

Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response.

Mark R Pett1, M Trent Herdman, Roger D Palmer, Giles S H Yeo, Mahmud K Shivji, Margaret A Stanley, Nicholas Coleman.   

Abstract

Integration of high-risk human papillomavirus (HRHPV) into the host genome is a key event in cervical neoplastic progression. Integration is associated with deregulated expression of the viral oncogenes E6 and E7 and acquisition of a selective growth advantage for cells containing integrants. Overexpression of the viral transcriptional regulator E2 from heterologous promoters has an inhibitory effect on transcription from integrated HRHPV. Therefore, we hypothesized that loss of E2-expressing episomes from cells in which integration had previously occurred would be required for such cells to gain a growth advantage. Using the unique W12 model of cervical squamous carcinogenesis, we show that cells containing integrated HPV16 reproducibly emerged during long-term culture when there had been a rapid fall in episome numbers. During the period of emergence, it is possible to isolate single-cell clones containing an intracellular mixture of the integrant being selected and episomes at reduced load. The lower level of E2 expression seen in such cells is associated with partial inhibition of transcription from the HPV16 integrant. Full deregulation is not observed until complete loss of E2-expressing episomes occurs. Microarray analysis showed that episome loss was closely associated with endogenous activation of antiviral response genes that are also inducible by the type I IFN pathway. Taken together, our results indicate that episome loss, associated with induction of antiviral response genes, is a key event in the spontaneous selection of cervical keratinocytes containing integrated HPV16. We conclude that cervical carcinogenesis requires not only HRHPV integration, but also loss of inhibitory episomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505361      PMCID: PMC1383496          DOI: 10.1073/pnas.0600078103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.

Authors:  S D Der; A Zhou; B R Williams; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 2.  The growth-inhibitory effects of TGF beta.

Authors:  R E Herrera
Journal:  Prog Mol Subcell Biol       Date:  1998

3.  Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes.

Authors:  R Klaes; S M Woerner; R Ridder; N Wentzensen; M Duerst; A Schneider; B Lotz; P Melsheimer; M von Knebel Doeberitz
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

4.  Human papillomavirus type 18 E6 protein binds the cellular PDZ protein TIP-2/GIPC, which is involved in transforming growth factor beta signaling and triggers its degradation by the proteasome.

Authors:  Arnaud Favre-Bonvin; Caroline Reynaud; Carole Kretz-Remy; Pierre Jalinot
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha.

Authors:  P Barnard; N A McMillan
Journal:  Virology       Date:  1999-07-05       Impact factor: 3.616

6.  Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31.

Authors:  Y E Chang; L A Laimins
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells.

Authors:  S Jeon; B L Allen-Hoffmann; P F Lambert
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

8.  Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm.

Authors:  A P Cullen; R Reid; M Campion; A T Lörincz
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

9.  Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity.

Authors:  L V Ronco; A Y Karpova; M Vidal; P M Howley
Journal:  Genes Dev       Date:  1998-07-01       Impact factor: 11.361

10.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

Authors:  F X Bosch; M M Manos; N Muñoz; M Sherman; A M Jansen; J Peto; M H Schiffman; V Moreno; R Kurman; K V Shah
Journal:  J Natl Cancer Inst       Date:  1995-06-07       Impact factor: 13.506

View more
  55 in total

1.  Cervical keratinocytes containing stably replicating extrachromosomal HPV-16 are refractory to transformation by oncogenic H-Ras.

Authors:  Kristi L Berger; Felicia Barriga; Michael J Lace; Lubomir P Turek; Gideon J Zamba; Frederick E Domann; John H Lee; Aloysius J Klingelhutz
Journal:  Virology       Date:  2006-08-30       Impact factor: 3.616

Review 2.  Human Papillomavirus Laboratory Testing: the Changing Paradigm.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

Review 3.  The human papillomavirus E7 oncoprotein as a regulator of transcription.

Authors:  William K Songock; Seong-Man Kim; Jason M Bodily
Journal:  Virus Res       Date:  2016-11-08       Impact factor: 3.303

4.  In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis.

Authors:  Elizabeth Gray; Mark R Pett; Dawn Ward; David M Winder; Margaret A Stanley; Ian Roberts; Cinzia G Scarpini; Nicholas Coleman
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

5.  Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene.

Authors:  Sojung Lee; Jung-Hee Kim; Heejong Kim; Jeong Woo Kang; Soo-Hyun Kim; Young Yang; Jinman Kim; JongSup Park; SurNie Park; JinTae Hong; Do-Young Yoon
Journal:  Immunology       Date:  2011-01-05       Impact factor: 7.397

6.  Effective formation of the segregation-competent complex determines successful partitioning of the bovine papillomavirus genome during cell division.

Authors:  Toomas Silla; Andres Männik; Mart Ustav
Journal:  J Virol       Date:  2010-09-01       Impact factor: 5.103

Review 7.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

8.  MicroRNA expression variability in human cervical tissues.

Authors:  Patrícia M Pereira; João Paulo Marques; Ana R Soares; Laura Carreto; Manuel A S Santos
Journal:  PLoS One       Date:  2010-07-26       Impact factor: 3.240

9.  High-resolution genomic profiling of human papillomavirus-associated vulval neoplasia.

Authors:  K J Purdie; C A Harwood; K Gibbon; T Chaplin; B D Young; J B Cazier; N Singh; I M Leigh; C M Proby
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

10.  The physical state of HPV16 infection and its clinical significance in cancer precursor lesion and cervical carcinoma.

Authors:  Wei Li; Wei Wang; Mani Si; Linfei Han; Qinglei Gao; Aiyue Luo; Yan Li; Yunping Lu; Shixuan Wang; Ding Ma
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-14       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.